Suhail Alam, MD
Retina Specialist · Phoenix, AZNPI 1316922818
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.6%), consulting fees and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AbbVie at 43.2% of the total. 2025 is the largest year on record at $11,185, more than ten times the $392 reported in 2019.
Across 132 payments — averaging $182.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Alimera Sciences, Inc.$10K
- Genentech USA, Inc.$737
- Apellis Pharmaceuticals, Inc.$673
- Regeneron Healthcare Solutions, Inc.$580
- Astellas Pharma US Inc$428
- plus $859 from 10 others
Across 50 payments — averaging $9068.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$280K
- Regeneron$98K
- AbbVie$41K
- Hoffmann-la Roche Limited$35K
What the payments were for
- Consulting fees$10,20042%
- Food & beverage$13,85458%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $10,401 |
| Alimera Sciences, Inc. | 24 | $10,376 |
| Genentech USA, Inc. | 32 | $737 |
| Apellis Pharmaceuticals, Inc. | 12 | $673 |
| Regeneron Healthcare Solutions, Inc. | 20 | $580 |
| Astellas Pharma US Inc | 11 | $428 |
| Novartis | 6 | $278 |
| Biogen | 6 | $271 |
| Bausch & Lomb Americas Inc. | 5 | $110 |
| Eyepoint US, Inc. | 2 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Tarsus Pharmaceuticals, Inc. | 1 | $36 |
| Amgen | 1 | $24 |
| Dompe US, Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,055 in reported general payments places this provider in the 70th percentile of 30 retina specialist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 546 | $15,977 |
| Ofloxacin | 456 | $4,773 |
| Bromfenac Sodium | 17 | $3,000 |
| Diclofenac Sodium | 153 | $1,676 |
| Latanoprost | 42 | $234 |
| Ketorolac Tromethamine | 14 | $202 |
| Timolol Maleate | 39 | $167 |
| Brimonidine Tartrate | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Phoenix
- Jordan GraffPhoenix$483K
- Rahul ReddyPhoenix$333K
- Henry KwongPhoenix$147K
- Benjamin BakallPhoenix$137K
- Jaime GaitanPhoenix$114K
- Stephen de SouzaPhoenix$95K
- Joseph BryanPhoenix$88K
- Alan GordonPhoenix$86K
- Rima PatelPhoenix$19K
- Matthew WelchPhoenix$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.